Health Care & Life Sciences » Pharmaceuticals | Catalyst Pharmaceutical Partners Inc.

Catalyst Pharmaceutical Partners Inc. | Mutual Funds

Mutual Funds that own Catalyst Pharmaceutical Partners Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total Stock Market Index Fund
2,401,801
2.34%
40,143
0%
07/31/2018
iShares Russell 2000 ETF
2,018,923
1.97%
-1,077
0.01%
09/06/2018
Vanguard Extended Market Index Fund
1,307,799
1.27%
0
0.01%
07/31/2018
iShares Russell 2000 Growth ETF
911,495
0.89%
0
0.03%
09/06/2018
Emerald Growth Fund
494,178
0.48%
494,178
0.12%
04/30/2018
Fidelity Spartan Extended Market Index Fund
403,697
0.39%
0
0.01%
07/31/2018
CREF Stock Account
304,545
0.3%
117,706
0%
03/31/2018
AST Small Cap Growth Portfolio
284,350
0.28%
0
0.1%
03/29/2018
iShares Micro Cap ETF
258,433
0.25%
0
0.08%
09/06/2018
Fidelity Spartan Total Market Index Fund
206,783
0.2%
0
0%
07/31/2018

About Catalyst Pharmaceutical Partners

View Profile
Address
355 Alhambra Circle
Coral Gables Florida 33134
United States
Employees -
Website http://www.catalystpharma.com
Updated 07/08/2019
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. The company was founded by McEnany J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.